Journal
UROLOGY
Volume 81, Issue 1, Pages 143-149Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2012.09.019
Keywords
-
Categories
Funding
- Novartis
- Pfizer
- GlaxoSmithKline
- Sanofi-Aventis
- Bayer
- Jannsen
- Boehringer-Ingelheim
- Sanofi
- Novartis Pharmaceuticals Corporation
Ask authors/readers for more resources
OBJECTIVE To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program. METHODS Patients with metastatic renal cell carcinoma refractory to vascular endothelial growth factor receptor-tyrosine kinase inhibitor received everolimus (10 mg once daily), with dosing interruption or modifications allowed for toxicity. All serious and grade 3/4 adverse events and grade 1/2 adverse events leading to a change in drug administration were reported. Tumor response was evaluated using Response Evaluation Criteria In Solid Tumors. RESULTS The study stratified 1367 evaluable patients into treatment duration groups of <3 months, >= 3 and <6 months, >= 6 months and <1 year, and >= 1 year. Pneumonia, noninfectious pneumonitis, and hyperglycemia occurred more frequently in patients receiving everolimus for >= 1 year but did not result in treatment discontinuations. First occurrence of adverse events presented early in the treatment course for most patients. Treatment duration of >= 6 months was associated with improved disease control rates. CONCLUSION Everolimus is well tolerated in patients with metastatic renal cell carcinoma for treatment durations >= 1 year and not associated with cumulative toxicity. UROLOGY 81: 143-149, 2013. (c) 2013 Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available